tiprankstipranks
Avenue Therapeutics Stockholders Approve Key Proposals
PremiumCompany AnnouncementsAvenue Therapeutics Stockholders Approve Key Proposals
8M ago
Avenue announces last patient last visit in Phase 1b/2a trial of AJ201
Premium
The Fly
Avenue announces last patient last visit in Phase 1b/2a trial of AJ201
9M ago
Avenue Therapeutics reports Q1 EPS ($15.40) vs ($101.57) last year
Premium
The Fly
Avenue Therapeutics reports Q1 EPS ($15.40) vs ($101.57) last year
9M ago
Avenue Therapeutics announces 1-for-75 reverse stock split
PremiumThe FlyAvenue Therapeutics announces 1-for-75 reverse stock split
10M ago
Navigating the Maze: Avenue Therapeutics Grapples with Regulatory Hurdles for IV Tramadol
Premium
Company Announcements
Navigating the Maze: Avenue Therapeutics Grapples with Regulatory Hurdles for IV Tramadol
11M ago
Avenue Therapeutics granted extension for Nasdaq compliance
Premium
The Fly
Avenue Therapeutics granted extension for Nasdaq compliance
11M ago
Avenue Therapeutics files to sell 33.08M shares of common stock for holders
PremiumThe FlyAvenue Therapeutics files to sell 33.08M shares of common stock for holders
1y ago
Avenue Therapeutics enters warrant exercise transactions for $5M in procceeds
Premium
The Fly
Avenue Therapeutics enters warrant exercise transactions for $5M in procceeds
1y ago
Avenue Therapeutics reaches final agreement with FDA for Phase 3 safety study
Premium
The Fly
Avenue Therapeutics reaches final agreement with FDA for Phase 3 safety study
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100